Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin (Curative Biotechnology, Inc.)
- Development stage
- Unknown
- Lead developer
- Curative Biotechnology
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Curative Biotechnology is developing a reformulated topical eye drop version of metformin hydrochloride for the treatment of intermediate dry Age-Related Macular Degeneration (AMD), Geographic Atrophy (GA), and other retinal degenerations. Unlike oral metformin used for diabetes, this formulation is designed for ophthalmic administration to deliver the drug directly to the choroid, retinal pigment epithelium (RPE), and retina. The mechanism of action involves the activation of AMP-activated protein kinase (AMPK) and the modulation of vascular endothelial growth factor (VEGF) and calcium-related signaling pathways, which are thought to provide neuroprotective effects and reduce retinal degeneration. The development is supported by a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) of the National Institutes of Health (NIH).
- Other names
- metformin hydrochloridemetformin eye dropsmetformin reformulation
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on metformin (Curative Biotechnology, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin (Curative Biotechnology, Inc.).